ORANGE COUNTY, Calif., Nov. 1, 2011 /PRNewswire/ -- NanoSmart Pharmaceuticals, Inc., a corporation developing novel cancer pharmaceuticals, has entered into a research collaboration with Children’s Hospital Los Angeles, one of the nation’s top pediatric hospitals, to develop and assess NanoSmart’s novel drug-delivery platform.
NanoSmart is developing a tumor-targeting platform utilizing human autoimmune antibodies that target areas of necrosis found in many different types of cancer. By combining these antibodies with different cancer drugs, NanoSmart plans to develop numerous novel biopharmaceutical products. NanoSmart’s drug-delivery system promises to increase the safety and efficacy of existing cancer drugs by increasing localization at the tumor site.
Collaborative research with Children’s Hospital Los Angeles will be conducted under the guidance of Timothy Triche, MD, PhD, Professor of Pathology and Pediatrics and Director of the Children’s Hospital Los Angeles Department of Pathology’s Center for Personalized Medicine.
“We are pleased to work with NanoSmart as part of our ongoing research program in nanoparticle-mediated therapy of Ewing’s sarcoma. This research will complement other research currently in progress in our lab. It is unique in that NanoSmart has leveraged a naturally occurring human antibody to target the nanoparticles to the tumor, which if successful should facilitate rapid approval from the FDA for use on Ewing’s sarcoma patients,” said Dr. Triche.
“This strategic alliance will give NanoSmart access to critical preclinical and clinical resources,” said Dr. James Smith, President of NanoSmart Pharmaceuticals. “In addition to Dr. Triche’s expertise and guidance, we look forward to initial characterization and testing of NanoSmart’s formulations in the unique model of metastatic Ewing’s Sarcoma at Children’s Hospital.”
About Children’s Hospital Los Angeles
Children’s Hospital Los Angeles has been named the best children’s hospital in California and among the best in the nation for clinical excellence with its selection to the prestigious US News & World Report Honor Roll. Children’s Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. The hospital is also one of America’s premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit www.CHLA.org.
NanoSmart Pharmaceuticals, Inc.
For more information visit:
www.nanosmartpharma.com
CONTACT:
Tel: (949) 305-2020
info@nanosmartpharma.com
SOURCE NanoSmart Pharmaceuticals, Inc.
